IMP761 — first LAG-3 agonist passes Phase I in autoimmune diseases
Analysis of IMP761 data from Immutep at EULAR 2026: a new class of drugs for treating rheumatoid arthritis without total immunosuppression. Safety, mechanism, and prospects. Read more.
